01170nas a2200445   4500000000100000000000100001000000100002008004100003653001000044653001100054653001900065653001900084653004800103653003900151653001200190653003300202653001500235653001000250653003200260100001500292700002300307700001300330700001300343700001200356700001200368700002100380700001400401700001500415700001700430700001500447700001600462700002100478700002300499700001600522245013800538250001500676300001200691490000700703020001400710       2024                            d10aAdult10aHumans10aBNT162 Vaccine10aCohort Studies10a*COVID-19/epidemiology/prevention & control10a*COVID-19 Vaccines/therapeutic use10aEstonia10aPost-Acute COVID-19 Syndrome10aSARS-CoV-210aSpain10aUnited Kingdom/epidemiology1 aM. Català1 aN. Mercadé-Besora1 aR. Kolde1 aN. Trinh1 aE. Roel1 aE. Burn1 aT. Rathod-Mistry1 aK. Kostka1 aW . Y. Man1 aA. Delmestri1 aH. Nordeng1 aA. Uusküla1 aT. Duarte-Salles1 aD. Prieto-Alhambra1 aA. Jödicke00aThe effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia  a2024/01/15  a225-2360 v12  a2213-2600